- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04135586
Effects of a Physical Exercise Intervention During Neoadjuvant Chemotherapy in Women With Breast Cancer (NEOLIFE)
Effects of a Physical Exercise Intervention at the Molecular Systemic and Tumor Level Performed During Neoadjuvant Chemotherapy in Women With Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Justification and aims Breast cancer is the fourth most common type of cancer worldwide and the first among women in Spain. It is also the type of cancer with the highest mortality. Several studies have assessed the effects of exercise performed in the neo-adjuvant period, but there is heterogeneity among them.
Principal aim:
To assess in women with triple-negative breast cancer receiving neo-adjuvant chemotherapy the effects of an intense physical exercise program (intervention group) on physical capacity, compared with a control group not meeting the minimum exercise recommendations of the World Health Organization (WHO).
Secondary aims:
To compare the following outcomes in both groups: body composition, and quality of life and depression/anxiety.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain
- Recruiting
- Hospital Universitario Quirónsalud de Pozuelo (HUQP)
-
Contact:
- Lucía G Cortijo, MD
- Phone Number: +34651835021
- Email: lgcortijo@gmail.com
-
Principal Investigator:
- Lucía G Cortijo
-
Madrid, Spain
- Recruiting
- Lgcortijo@Gmail.Com
-
Contact:
- Lucía G Cortijo, MD
- Phone Number: +34651835021
- Email: lgcortijo@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosed with breast carcinoma in the 'Hospital Universitario Quirónsalud de Pozuelo' (Madrid, Spain) and following neoadjuvant therapy in the aforementioned center.
- Must have triple negative breast cancer (i.e., negative for estrogen receptors, progesterone receptors, and excess HER2 protein) of size > or equal to 15 mm
Exclusion Criteria:
- Not meeting all of the above.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exercise
The patients in this arm will follow an exercise program for 24 weeks (i.e., during neo-adjuvant treatment), with two sessions per week including both aerobic and resistance training.
Exercise intensity will range between 65% and 100% of the maximum score in the scale of Rated Perceived Exertion (RPE).
|
Exercise program for 24 weeks (with neo-adjuvant treatment), with two sessions per week including both moderate-to-intense aerobic and resistance training.
The intensity of each type of exercise will range between 65% and 100% of the maximum score in the Rated Perceived Exertion (RPE) scale.
|
Other: Control
The patients follow their usual habits as well as a Yoga program.
They will also receive educational sessions on the benefits of regular physical activity (brisk walking).
|
Yoga + educational program
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiorespiratory fitness
Time Frame: Change from baseline to end of intervention (i.e., after 24 weeks)
|
peak rate of oxygen consumption (ml/kg/min) reached during a graded treadmill exercise test until exhaustion
|
Change from baseline to end of intervention (i.e., after 24 weeks)
|
muscle dynamic strength
Time Frame: Change from baseline to end of intervention (i.e., after 24 weeks)
|
Time (seconds) to perform the sit-to-stand (STS) test (five consecutive repetitions of sitting down and uprising from a chair)
|
Change from baseline to end of intervention (i.e., after 24 weeks)
|
handgrip strength
Time Frame: Change from baseline to end of intervention (i.e., after 24 weeks)
|
handgrip strength measured using a dynamometer and scores recorded in kilograms (to the nearest 0.1 kg)
|
Change from baseline to end of intervention (i.e., after 24 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health-related quality of life (Breast Cancer-Specific Quality of Life Questionnaire [QLQ-BR23])
Time Frame: Change from baseline to end of intervention (i.e., after 24 weeks)
|
The QLQ-C30 is a multidimensional cancer HRQoL questionnaire that contains 30 items assessing six functional and nine symptom scales.
Results from this questionnaire are transformed into scores ranging from 0 to 100 according to European Organization for Research and Treatment of Cancer (EORTC) scoring, with higher scores in the functioning scales indicating a better functional status and global HRQoL, and higher scores on the symptoms' scales indicating more symptoms.
|
Change from baseline to end of intervention (i.e., after 24 weeks)
|
Body composition (fat mass)
Time Frame: Change from baseline to end of intervention (i.e., after 24 weeks)
|
fat mass (% of whole body mass), evaluated by dual energy X-ray absorptiometry
|
Change from baseline to end of intervention (i.e., after 24 weeks)
|
Body composition (lean body mass)
Time Frame: Change from baseline to end of intervention (i.e., after 24 weeks)
|
lean body mass (% of whole body mass), evaluated by dual energy X-ray absorptiometry
|
Change from baseline to end of intervention (i.e., after 24 weeks)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- UEM Quirón
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Physical Exercise
-
Paracelsus Medical UniversityDepartment of Psychiatry University of BonnRecruitingHealthy | Exercise | Physical Fitness | Exercise TestAustria
-
University of BaghdadNisreen Hameed JeburCompleted
-
East Carolina UniversityCompletedPhysical ExerciseUnited States
-
University of Alabama at BirminghamLakeshore FoundationWithdrawnExercise | Disability Physical
-
Nathaniel JenkinsCompletedExercise Training | Physical Exertion | Desire to ExerciseUnited States
-
Northeastern UniversityActive, not recruitingPhysical Activity | ExerciseUnited States
-
University of MalayaCompletedPhysical Activity | ExerciseMalaysia
-
University of Nove de JulhoFundação de Amparo à Pesquisa do Estado de São PauloCompletedExcessive Physical Exercise, UnspecifiedBrazil
-
University of California, Los AngelesCompletedExcessive Physical Exercise, UnspecifiedUnited States
-
University of SevilleCompletedGait | Physical Therapy | Sports Physical Therapy | Exercise TherapySpain
Clinical Trials on Exercise training
-
University of British ColumbiaMichael Smith Foundation for Health ResearchCompleted
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Universidade Norte do ParanáCompleted
-
University of Colorado, DenverVA Eastern Colorado Health Care SystemCompletedHealthy | Overweight | Type 2 Diabetes Mellitus | Cardiovascular Risk FactorUnited States
-
National Taiwan University HospitalCompletedAtrial FibrillationTaiwan
-
Universita di VeronaRecruiting
-
Hacettepe UniversityCompleted
-
Toronto Rehabilitation InstituteCompletedAcute Myeloid LeukemiaCanada
-
University of LeipzigCompletedImpact of Intensive Exercise Training on Coronary Collateral Circulation in Patients With Stable CADStable Coronary Artery DiseaseGermany
-
Helse Stavanger HFStavanger Health ResearchCompletedVentricular TachycardiaNorway